Last reviewed · How we verify

Faster-acting Aspart insulin Fiasp

Rigshospitalet, Denmark · Phase 3 active Small molecule

Faster-acting Aspart insulin Fiasp is a Rapid-acting insulin analog Small molecule drug developed by Rigshospitalet, Denmark. It is currently in Phase 3 development for Type 1 diabetes mellitus, Type 2 diabetes mellitus. Also known as: Insulin Fiasp.

Fiasp is a rapid-acting insulin analog that binds to the insulin receptor to facilitate glucose uptake and utilization in peripheral tissues.

Fiasp is a rapid-acting insulin analog that binds to the insulin receptor to facilitate glucose uptake and utilization in peripheral tissues. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

At a glance

Generic nameFaster-acting Aspart insulin Fiasp
Also known asInsulin Fiasp
SponsorRigshospitalet, Denmark
Drug classRapid-acting insulin analog
TargetInsulin receptor
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 3

Mechanism of action

Fiasp (faster-acting insulin aspart) is a modified version of insulin aspart formulated with niacinamide and L-arginine to accelerate absorption from subcutaneous injection sites. It reaches peak insulin levels faster than standard insulin aspart, allowing for more rapid postprandial glucose control. Like all insulins, it works by binding to insulin receptors on muscle and adipose tissue cells, promoting glucose uptake and storage while suppressing hepatic glucose production.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Faster-acting Aspart insulin Fiasp

What is Faster-acting Aspart insulin Fiasp?

Faster-acting Aspart insulin Fiasp is a Rapid-acting insulin analog drug developed by Rigshospitalet, Denmark, indicated for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

How does Faster-acting Aspart insulin Fiasp work?

Fiasp is a rapid-acting insulin analog that binds to the insulin receptor to facilitate glucose uptake and utilization in peripheral tissues.

What is Faster-acting Aspart insulin Fiasp used for?

Faster-acting Aspart insulin Fiasp is indicated for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

Who makes Faster-acting Aspart insulin Fiasp?

Faster-acting Aspart insulin Fiasp is developed by Rigshospitalet, Denmark (see full Rigshospitalet, Denmark pipeline at /company/rigshospitalet-denmark).

Is Faster-acting Aspart insulin Fiasp also known as anything else?

Faster-acting Aspart insulin Fiasp is also known as Insulin Fiasp.

What drug class is Faster-acting Aspart insulin Fiasp in?

Faster-acting Aspart insulin Fiasp belongs to the Rapid-acting insulin analog class. See all Rapid-acting insulin analog drugs at /class/rapid-acting-insulin-analog.

What development phase is Faster-acting Aspart insulin Fiasp in?

Faster-acting Aspart insulin Fiasp is in Phase 3.

What are the side effects of Faster-acting Aspart insulin Fiasp?

Common side effects of Faster-acting Aspart insulin Fiasp include Hypoglycemia, Injection site reactions, Weight gain, Lipodystrophy.

What does Faster-acting Aspart insulin Fiasp target?

Faster-acting Aspart insulin Fiasp targets Insulin receptor and is a Rapid-acting insulin analog.

Related